Beyond Air (XAIR) Q4 2026 Earnings Call Transcript

Beyond Air posted fiscal 2026 revenue of $7.7 million, up 107% year-over-year, and guided fiscal 2027 revenue to $16-18 million—implying growth above 110%. The medical device company locked in a 90% customer renewal rate for its LungFit PH nitric oxide delivery system and flipped to gross profitability at $300,000 for the fiscal year.

Management expects FDA approval of its second-generation LungFit device in late 2026, a catalyst that underpins the aggressive revenue outlook. The company secured three major group purchasing organization agreements covering roughly 7,000 hospitals, expanding potential market access significantly. Beyond Air also cut net cash burn by 56%, easing near-term financing pressure.

The Gen 2 device approval and commercial rollout represent the key inflection point. If the timeline holds, the installed base expansion through GPO contracts should accelerate utilization. The 90% renewal rate suggests sticky adoption among early hospital customers, reducing churn risk as the company scales.